Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention

Lancet Oncology

Volumn 3, Issue 3, 2002, Pages 166-174

  Chan, Timothy A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ACETYLSALICYLIC ACID; ANTHRANILIC ACID; CYCLOOXYGENASE 2 INHIBITOR; EKI 785; EPIDERMAL GROWTH FACTOR RECEPTOR; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; LIPOXYGENASE INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PIROXICAM; PLACEBO; PROPIONIC ACID; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; RECEPTOR BLOCKING AGENT; ROFECOXIB; SALICYLIC ACID; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CATALYSIS; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; REVIEW; STOMACH ULCER;

EID: 0036521678     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00680-0     Document Type: Review

References (86)

1. Cantor D, Cancer. In: Bynum WF, Porter R, (Eds). Companion Encyclopedia of the History of Medicine. London: Routledge, 1993: 552.
2. Tattersal MHN, Thomas H. Recent advances: oncology. BMJ 1999; 318:445-48.
3. Kune S, Kune GA, Watson L. The Melbourne Colorectal Cancer Study: incidence findings by age, sex, site, migrants and religion. Int J Epidemiol 1986; 15: 483-93.
4. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-04.
5. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-96.
6. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-46.
7. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-16.
8. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-39.
9. Nugent K, Farmer K, Spigelman A, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618-19.
10. Rigau J, Pique JM, Rubio E, et al. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991; 115: 952-54.
11. Thorson A, Lynch H, Smyrk T. Rectal cancer in FAP patient after sulindac. Lancet 1994; 343: 180.
12. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989; 157: 175-79.
13. Winde G, Gumbinger HG, Osswald H, et al. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 1993; 8: 13-17.
14. Winde G, Schmid K, Schlegel W, et al. Complete reversion and prevention of rectal adenomas in colectornized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995; 38: 813-30.
15. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991; 253: 661-65.
16. Jones D, Carlton D, McIntyre T, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-54.
17. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-42.
18. Beazer-Barclay Y, Levy DB, Moser AM, et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 1996; 17: 1757-60.
19. Chiu C-H, McEntee MF, Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997; 57: 4267-73.
20. Mahmoud NN, Boolbol SK, Dannenberg AJ, et al. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998; 19: 87-91.
21. Boolbol SK, Dannenberg AJ, Chadurn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56: 2556-60.
22. Mahmoud N, Dannenberg A, Mestre J, et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998; 124: 225-31.
23. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the APC-Min mouse by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56: 710-14.
24. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61: 1733-40.
25. Wechter W, Kantoci D, Murray E, et al. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 1997; 57: 4316-24.
26. Chiu CH, McEntee MF, Whelan J. Discordant effect of aspirin and indomethacin on intestinal tumor burden in APC (Min/+) mice. Prostaglandins Leukot Essent Fatty Acids 2000; 62: 269-75.
27. Moorghen M, Ince P, Finney KJ, et al. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol 1988; 156: 341-47.
28. Skinner SA, Penney AG, O'Brien PE. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 1991; 126: 1094-96.
29. Pollard M, Luckert PH. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981; 214: 558-59.
30. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6: 1024-28.
31. Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. Journal of Cell Science 1994; 107: 3569-77.
32. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55: 1811-16.
33. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-98.
34. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96: 491-503.
35. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci, USA 1998; 95: 681-86.
36. Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 222: 179-88.
37. Qiao L, Hanif R, Sphicas E, et al. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol 1998; 55: 53-64.
38. Elder DJ, Halton DE, Crew TE, Paraskeva C. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 2000; 86: 553-60.
39. Smith ML, Hawcroft G, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 2000; 36: 664-74.
40. Piazza GA, Rahm ALK, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing Apoptosis. Cancer Res 1995; 55: 3110-16.
41. Lu X, Xie W, Reed D, et al. Nonsteroidal anti-inflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA 1995; 92: 7961-65.
42. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-35.
43. Vane JR. Introduction: mechanism of action of NSAIDs. Br J Rheumatol 1996; 35(suppl 1): 1-3.
44. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-88.
45. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58: 4823-26.
46. Yang VW, Shields JM, Hamilton SR, et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998; 58: 1750-53.
47. Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111: 1134-40.
48. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996: 1259-62.
49. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518-23.
50. Kinzler KW, Vogelstein B. Lessons from hereditary colon cancer. Cell 1996; 87: 159-70.
51. Tsujii M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
52. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in APC (716) knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-09.
53. Mei JM, Hord NG, Winterstein DF, et al. Differential expression of prostaglandin endoperoxide H synthase-2 and formation of activated beta-catenin-LEF-1 transcription complex in mouse colonic epithelial cells contrasting in APC. Carcinogenesis 1999; 20: 737-40.
54. Sheng HM, Shao JY, Morrow JD, et al. Modulation of apoptosis and bcl-2 expression by prostaglandin E-2 in human colon cancer cells. Cancer Res 1998; 58: 362-66.
55. Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1995; 1258: 215-23.
56. Roberts RA, James NH, Woodyatt NJ, et al. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis 1998; 19: 43-48.
57. Tsubouchi Y, Sano H, Kawahito Y, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000; 270: 400-05.
58. Jayadev S, Linardic CM, Hannun YA. Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha. J Biol Chem 1994; 269: 5757-63.
59. Jayadev S, Hayter HL, Andrieu N, et al. Phospolipase A2 is necessary for tumor necrosis factor alpha-induced ceramide generation in L929 cells. J Biol Chem 1997; 272: 17196-203.
60. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996; 274: 1855-59.
61. Kolesnick RN, Haimovitz-Friedman A, Fuks Z. The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation. Biochem Cell Biol 1994; 72: 471-74.
62. Cao Y, Pearman AT, Zimmerman GA, et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000; 97: 11280-85.
63. Scorrano L, Penzo D, Petronilli V, et al. Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha apoptotic signaling. J Biol Chem 2001; 276: 12035-40.
64. Fonteh AN, LaPorte T, Swan D, McAlexander MA. A decrease in remodeling accounts for the accumulation of arachidonic acid in murine mast cells undergoing apoptosis. J Biol Chem 2001; 276: 1439-49.
65. Ikawa H, Kamitani H, Calvo BF, et al. Expression of 15-lipoxygenase-1 in human colorectal cancer. Cancer Res 1999; 59: 360-66.
66. Steele VE, Holmes CA, Hawk ET, et al. Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs 2000; 9: 2121-38.
67. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta 1996; 1300: 240-46.
68. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57: 2909-15.
69. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-45.
70. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NFκB pathway. J Biol Chem 1999; 274; 27307-14.
71. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NFκB activation. Science 1996; 274: 1383-85.
72. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-45.
73. Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 2000; 97: 13275-80.
74. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
75. Skopinska-Rozewska E, Piazza GA, Sommer E, et al. Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN-1): a potential mechanism for their antineoplastic properties. Int J Tissue React 1998; 20: 85-89.
76. Shureiqi I, Chen D, Lotan R, et al. 15-lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000; 60: 6846-50.
77. Spanbroek R, Hildner M, Kohler A, et al. IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc Natl Acad Sci USA 2001; 98: 5152-57.
78. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001; 61: 6307-12.
79. Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001; 28: 105-07.
80. Masunaga R, Kohno H, Dhar DK, et al. Enhanced apoptosis and transforming growth factor-beta 1 expression in colorectal adenomas and carcinomas after sulindac therapy. Dis Colon Rectum 2001; 44: 100-15.
81. Baek SJ, Kim KS, Nixon JB, et al. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59: 901-08.
82. Marks F, Muller-Decker K, Furstenberger G. A causual relationship between unscheduled eicosanoid signaling and tumor development: cancer chemoprevention by inhibitors of arachidonic acid metabolism. Toxicology 2000; 153: 11-26.
83. Furstenberger G, Gross M, Marks F. Eicosanoids and multistage carcinogenesis in NMRI mouse skin: role of Prostaglandins E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion). Carcinogenesis 1989; 10: 91-96.
84. Marnett LJ. Aspirin and the potential role of Prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89.
85. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1084-86.
86. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-56.